BMO Capital Starts Aquestive Therapeutics (AQST) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
RBC Capital Starts Aquestive Therapeutics (AQST) at Outperform
August 20, 2018 8:07 AM EDTRBC Capital analyst Randall Stanicky initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with an Outperform rating and a price target of $23.00.
Stanicky said with stable cash flows from Suboxone behind it and a broad pipeline ahead of it, AQST is well... More
JMP Securities Starts Aquestive Therapeutics (AQST) at Market Outperform
August 20, 2018 5:06 AM EDTJMP Securities analyst Jason Butler initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Market Outperform rating and a price target of $29.00.
The analyst comments "The company's lead pipeline candidates address neurological diseases, where Aquestive is building commercial capabilities as it grows to... More
